Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 2/20 | 0.41 |
| ▸ | SPR | P35270 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652473 | 1.00 | USP30 (0.47) | USP30LIPESPRNR1H2GPR119 | |
| SCHEMBL930035 | 0.89 | USP30 (0.43) | USP30LIPESPRGPR119HSD17B10 | |
| SCHEMBL6325451 | 0.89 | USP30 (0.43) | USP30LIPESPRGPR119HSD17B10 | |
| SCHEMBL18701742 | 0.89 | USP30 (0.47) | USP30LIPESPRNR1H2GPR119 | |
| SCHEMBL18711404 | 0.85 | USP30 (0.47) | USP30SPRNR1H2GPR119HSD17B10 | |
| SCHEMBL18701830 | 0.81 | USP30 (0.52) | USP30LIPESPRNR1H2GPR119 | |
| SCHEMBL14196289 | 0.81 | USP30 (0.57) | USP30LIPESPRNR1H2GPR119 | |
| SCHEMBL3580062 | 0.80 | USP30 (0.33) | USP30 | |
| SCHEMBL3572947 | 0.80 | USP30 (0.33) | USP30 | |
| SCHEMBL18701890 | 0.80 | SPR (0.42) | USP30SPRNR1H2GPR119HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005614-B | Pyrimidine pyridine CDK inhibitor and preparation method and application thereof | 中国药科大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-118005614-A | Pyrimidine pyridine CDK inhibitor and preparation method and application thereof | 中国药科大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-117659025-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-03-08 | — | — | CN | disclosed |
| CN-117586108-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586191-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-111542515-B | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2023-12-05 | — | — | CN | disclosed |
| CN-111542515-A | TOLL-like receptor 8(TLR8) specific antagonist and preparation method and application thereof | 科罗拉多州立大学董事会法人团体 | 2020-08-14 | — | — | CN | disclosed |
| US-8367838-B2 | Amines or amino alcohols as GLYT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | KOLCZEWSKI SABINE (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | ABBOTT LABORATORIES (US) | 2008-04-17 | — | — | US | disclosed |
| US-7332504-B2 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2008-02-19 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-6833370-B1 | Selectively controlling neurotransmitter release; such as n-((3)-1-(6-chloro-3-pyridinyl)pyrrolidinyl)-n-methylamine | ABBOTT LABORATORIES | 2004-12-21 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1428824-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | USP30 4053/4885LIPE 2083/4885SPR 4564/4885 |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | USP30 4053/4885LIPE 2083/4885SPR 4564/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | USP30 4324/4885LIPE 2281/4885SPR 4549/4885 |
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | GRIN3A, GAP43, GRIN3B | USP30 4503/4885LIPE 4402/4885SPR 2984/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | USP30 4324/4885LIPE 2281/4885SPR 4549/4885 |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | USP30 3738/4885LIPE 2505/4885SPR 1342/4885 |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | GRIN3A, GAP43, GRIN3B | USP30 4503/4885LIPE 4402/4885SPR 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.